---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-019153"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:34:15.375075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics Q1 net loss $8.2M; cash $41.8M; LCA5 gene therapy shows sustained 12-month efficacy

## Summary
- Net loss of $8.2M ($0.24 per share) vs $7.1M ($0.29) in Q1 2024.
- Cash and equivalents $41.8M; management expects runway into Q2 2026.
- License revenue from Viatris was $4.4M, up from $1.7M YoY, primarily R&D reimbursement.
- OPGx-LCA5 Phase 1/2 data at ARVO show durable efficacy at 12 months; pediatric cohort enrollment started.
- Topline data for LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials expected mid-2025 and H1 2025, respectively.

## SEC filing metadata
- accession: 0001140361-25-019153
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/0001140361-25-019153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/ef20049034_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-019153
- JSON: https://secwatch.observer/filing/0001140361-25-019153.json
- Plain text: https://secwatch.observer/filing/0001140361-25-019153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.